Oral Cancer Clinical Trial
Official title:
A Phase I Study of Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Background:
Head and neck cancer is a group of cancers that start in the mouth, nose, throat, larynx and
sinuses. The usual treatment is surgery, radiation, chemotherapy, or a combination of those.
Approximately 50% of HPV-negative head and neck cancer patients that have been treated with
any of these modalities will have a recurrence. For these patients, current treatment options
include surgery and re-irradiation with chemotherapy, which can reduce symptoms and may stop
the tumor from growing but in the majority of cases, only for a few months. In this trial,
researchers want to see if they can cure or significantly lower the chance of head and neck
cancer growing back or spreading by adding the new agent birinapant to re-irradiation.
Objective:
To test the safety of birinapant and re-irradiation at different doses in patients with head
and neck cancer.
Eligibility:
Adults age 18 and older with head and neck cancer who are candidates for re-irradiation.
Design:
Participants will be screened with a review of their medical record. Participants will have
exams and procedures that are part of their usual care. Participants will also have a test of
heart activity before treatment.
Participants will have urine pregnancy tests, if female.
Participants will have blood and tumor samples taken 2 times and stored for research. The
study lasts 6 weeks.
Participants will get radiation for 5 days a week (Monday Friday) for all 6 weeks.
Participant will get the study drug on 4 Tuesdays. They will get it in an arm vein over 30
minutes each time.
About 4 weeks after the study ends, participants will have a follow-up visit. They will have
a physical exam, health questions, and blood tests.
Participants may have scans 4 times over the next 2 years. Participants will get an email or
phone call every 6 months.
Sponsoring Institute: National Cancer Institute
Status | Recruiting |
Enrollment | 34 |
Est. completion date | October 31, 2021 |
Est. primary completion date | October 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
- INCLUSION CRITERIA: - Patients must have histologically or cytologically confirmed locally recurrent HNSCC for whom re-irradiation for local control is considered standard of care. Patients with potentially reactive benign nodes will not be excluded. - Patients with HPV-negative or HPV-positive head and neck cancer are eligible. - Patients who have had prior treatment with immune therapies are eligible. - Patients must have received curative-intent platinum- and/or cetuximab-based chemoradiotherapy. - Patients must have completed their last treatment dose with chemotherapy or immunotherapy at least 4 weeks (6 weeks for nitrosoureas or mitomycin C) before enrolling on study. - Patients must have completed their last treatment dose with radiotherapy at least 6 months before enrolling on study. - Patients who have had major surgery must be fully recovered and require a recovery period of at least 4 weeks prior to enrolling on study. - Age greater than or equal to 18 years. - ECOG performance status less than or equal to 2 (see Appendix A). - Patients must have normal organ and marrow function as defined below: - Hemoglobin greater than or equal to 10 g/dL (transfusion permitted) - Absolute neutrophil count greater than or equal to 1,500/mcL - Platelets greater than or equal to 75,000/mcL - Total bilirubin within 1.5 x the upper limit of normal (ULN) institutional limits - AST(SGOT)/ALT(SGPT) less than or equal to 2.5 (SqrRoot) institutional upper limit of normal - Creatinine clearance greater than or equal to 60 mL/min/1.73 m squared for patients with creatinine levels above institutional normal. - Patients must have a QTc less than or equal to 480 msec. - Ability to understand and the willingness to sign a written informed consent document. - Patients must have measurable disease. EXCLUSION CRITERIA: - Eligibility for curative-intent surgery. - More than 2 lines of palliative systemic therapy (platinum-, taxane- or cetuximabbased chemotherapy or immunotherapy) - Patients who are receiving any other investigational agents. - Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. - History of allergic reactions attributed to compounds of similar chemical or biologic composition to birinapant. - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Pregnant women are excluded from this study because birinapant may have potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with birinapant, breastfeeding should be discontinued prior to enrollment. - HIV positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with birinapant. - Patients requiring the use of anti-tumor necrosis factor (anti TNF) therapies, such as infliximab, or patients who have received treatment with anti-TNF therapies within 5 half-lives of the drug (48 days for infliximab, 55 days for golimumab, 70 days for certolizumab and adalimumab, and16 days for etanercept). - Patients with previous exposure to birinapant. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center | Bethesda | Maryland |
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015 Jan 29;517(7536):576-82. doi: 10.1038/nature14129. — View Citation
Eytan DF, Snow GE, Carlson S, Derakhshan A, Saleh A, Schiltz S, Cheng H, Mohan S, Cornelius S, Coupar J, Sowers AL, Hernandez L, Mitchell JB, Annunziata CM, Chen Z, Van Waes C. SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2. Cancer Res. 2016 Sep 15;76(18):5442-5454. doi: 10.1158/0008-5472.CAN-15-3317. Epub 2016 Jul 28. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated dose | Maximum tolerated dose of birinapant administered concurrently with IMRRT | While on therapy and 2 years post-therapy | |
Primary | Brinipart toxicities | Toxicities of birinapant administered concurrently with IMRRT | While on therapy and 2 years post-therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06031337 -
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
|
||
Completed |
NCT00158678 -
IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC
|
Phase 3 | |
Completed |
NCT00933387 -
A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma
|
Phase 2 | |
Enrolling by invitation |
NCT05030597 -
Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
|
N/A | |
Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
Recruiting |
NCT03684707 -
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions
|
Phase 4 | |
Recruiting |
NCT06130332 -
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
|
Phase 2 | |
Recruiting |
NCT04372914 -
Prevention of Oral DNA Damage by Black Raspberries
|
N/A | |
Active, not recruiting |
NCT03529422 -
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
|
Phase 2 | |
Recruiting |
NCT03686020 -
Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study)
|
||
Not yet recruiting |
NCT06060288 -
Diagnostic Accuracy of Mobile Phone Imaging Compared to Conventional Clinical Examination for Oral Cancer Screening
|
||
Withdrawn |
NCT00951470 -
Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema
|
N/A | |
Completed |
NCT00964977 -
Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.
|
Phase 3 | |
Completed |
NCT01418118 -
Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery
|
Phase 4 | |
Active, not recruiting |
NCT00232960 -
Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC
|
N/A | |
Recruiting |
NCT05429099 -
Mandibular Reconstruction Preplanning (ViPMR)
|
Phase 2/Phase 3 | |
Completed |
NCT04614896 -
Use of Ultrasound for Measuring Size of Oral Tongue Cancers
|
N/A | |
Recruiting |
NCT03685409 -
Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions
|
Phase 3 | |
Completed |
NCT00402779 -
Erlotinib Prevention of Oral Cancer (EPOC)
|
Phase 3 | |
Recruiting |
NCT05153733 -
Improved Implant for Reconstruction Purposes After Mandibular Resection
|
N/A |